RSS

CYDY CytoDyn Inc

Mod: mightycydy Asst: HHIGambler,CaptnAmerca
Last Post: 11:32 PM
Followers: 439
Posts Today: 27
Views Today: 52279

CYDY Stock Quote & Tools

$0.2054 ▲ +0.0054 (+2.69%) As of Oct 15, 3:59 PM EDT
Last0.2054
$ Chg0.0054
Open0.2000
High0.2090
Beta1.4964
Year High0.397
Market Cap301.80M
P/B Ratio-2.68
EPS-0.04
Avg Vol (30d)1.57M
Volume3.28M
% Chg+2.69%
Prev Close0.2000
Low0.1971
VWAP0.20198
Year Low0.183
Total Shares1.47B
Shares Out1.47B
Float1.36B
ExchangeOTCQB
Healthcare Biotechnology & Life Sciences
Company Profile Buy Rating Time & Sales News Filings Financials

CYDY Stock Message Board Discussion

3 Pinned Posts
Leronlimab (Pro 140) Cliff Notes What is it? Leronlimab is a humanized monoclo (43) by trding
Leronlimab Regulator List (a work in progress) = upregulation = downregulation a-SMA (21) by ohm20
EIND: Information to Submit to Doctors Leronlimab a humanized monoclonal antibody binds CCR5, (38) by ohm20
  1. havasu78

    Thanks, ohm. thats all very logical. But for the logic to hold true, does it not require that

    (2)
  2. WUM

    Sepsis is also included in Ohm's List of Indications for LL.A study on the prevalence of sepsis in

    (1)
  3. lorbas

    BP paper:

    (1)
  4. mtruong34

    Me too. Just bought another 1500 shares lol.

    (1)
  5. Borel Fields

    To restate: Samsung gave CytoDyn a $34m loan of at least a year's duration via "non-standard

    (8)
  6. CDiddy

    Me too. Lol

  7. morokoy

    Bottom of page 37 Current 10Q Nov.30. Under the Samsung Agreement, the purchase order is

    (3)
  8. nmbr1stckpckr

    I shouldn't have read this thread. I was content just waiting for the CD12 results. But

    (5)
  9. ClosetInvestor

    According to the 10Q released today, CYDY negotiated with Samsung for non-standard payments. The

    (4)
  10. Shelly2626

    Definitely right on !!!! Going to be fun the next couple weeks GLTA

  11. mtruong34

    I don't think OLE gets added to the CD12 trial analysis, only the RCT portion. OLE outcomes may be

    (3)
  12. calstang

    Seems to me the final ratio will be somewhere near 300 to 132 due to ongoing enrollment in the open

    (2)
  13. CDiddy

    The 42 day metric was a suggestion from the DSMC for the 75% review. Never added as an

    (3)
  14. JLang

    The first letter of each sentence spells out "T R I P L E D I G I T S"?

    (2)
  15. nmbr1stckpckr

    Has anyone sussed out the 'clever' thing MM did with the financials?

  16. calstang

    I thought our s/c trial end was extended out to 42 days? Does that mean the 28 day will be a peak,

  17. Dr Zaius

    From the 10-Q: Note 4. Long-Term Accounts Payable During the quarter ended November 30,

    (10)
  18. MarcS

    They said at least twice it's 394. Here's from page 31 of today's 10-Q: The Company

    (2)
  19. CDiddy

    Not to mention that some will be excluded from the final numbers due to non

  20. CDiddy

    Good point. Even if they need to do another conversion, if EUA is likely it will be an easy

  21. ohm20

    Good catch, I can't believe I didn't figure that out.

    (1)
  22. calstang

    At a 50% death rate reduction, I don't think the trial would have been halted. I think we would

    (2)
  23. TechGuru

    Marc$, The trial ratio is 2:1 so it would be only possible to have 393 (262/131). Patients

    (1)
  24. MarcS

    I have often wondered if that was the plan they had in mind: Or convert more of fifes

    (3)
  25. CDiddy

    I have no idea what that is, but I'm down.

  26. CDiddy

    Sorry, that's what I meant. Sell shares to pay down debt. Or convert more of fifes

    (3)
  27. MarcS

    Even with the # being 394, not 390, in the clinical trial? Everyone seems to be using 390, but

    (2)
  28. mtruong34

    Totally worth it to get uplisting IMO.

  29. ohm20

    Thus, it it quite conceivable that at 50% and/or at 75% interim analysis, that we did

    (7)
  30. TechGuru

    :) Deal, I will have as back-up a bottle of Three Wood Auchentoshan.

  31. ohm20

    Paying down debt with current assets just shifts numbers from one column to another. A small share

    (1)
  32. calstang

    The HaybittlePeto boundary is a rule for deciding when to stop a clinical trial prematurely. It

    (6)
  33. MarcS

    For the quarterly period ended November 30, 2020 So, no, that's not how they would

    (2)
  34. CDiddy

    I believe by paying down debt.

    (1)
  35. CDiddy

    Tech, If you are right I will fly to you and buy you a round. I am trying to mitigate my

  36. TechGuru

    Calstang, Just to be clear, 51 deaths will NOT meet p-value (0.0813 2-tailed). 50

  37. grow

    Another reason could simply be that that they expect to be busier after CD12 completes, so why not

    (1)
  38. mtruong34

    I'm with you on this one. Rushing to complete 10-Q to time uplisting prior to cd12 is the only

    (2)
  39. ohm20

    Nobody understands the importance of prior art.

    (2)
  40. TechGuru

    CDiddy, Yup. COVID show-time has arrived and now is down to cold numbers only. Of course,

    (5)
  41. Zadie

    Thanks CD. I will contact him with your information. Zadie

  42. CDiddy

    Yes that sounds like long haulers. Hopefully the trial sites are listed soon. You might reach

  43. calstang

    I understand, that is a good way to look at it, a good way to do the math. Thus, if out of the 87,

    (2)
  44. CDiddy

    That's what I'm hearing as well. Trying to think of other reasons (beside uplisting) that they

  45. Zadie

    CDiddy and all, Need your help. someone from one of my supplier got COV19 back in late Feb 2020.

  46. mtruong34

    I believe NP said it was due January 15 in the CC.

    (1)
  47. mtruong34

    My theory is that they are rushing the 10-Q so that any potential uplisting would occur before CD12

    (3)
  48. CDiddy

    Can anyone verify that this 10Q wasn't due for another week?

  49. CDiddy

    I cannot wait for our predictions to be validated. We may very well be in the cusp of proving a

    (10)
  50. mtruong34

    Sharing cost analysis by username Bridge to sell from YMB: Ok, so the big news today is the

    (13)

Top 10 Most Recent News Articles

More News Articles

Top 5 Most Recently Viewed Articles

Investigation of Stock Transactions: TASK, VBTX, TURN Insights

Updated Category News Views 125

Financial Investigations for Shareholders of TASK, VBTX, and TURN Halper Sadeh LLC is actively investigating several companies regarding potential violations of federal securities laws affecting shareholders. The investigations focus on significant transactions involving TaskUs, Veritex Holdings, and 180 Degree Capital Corp. TaskUs, Inc. and Its Acquisition by Blackstone...

Continue Reading
Comprehensive Analysis of NVIDIA in the Semiconductor Market

Updated Category News Views 678

Understanding NVIDIA's Position in the Semiconductor Sector In today's fast-paced business environment, it is crucial for investors and industry followers to conduct in-depth analyses of key companies. This article offers a detailed comparison of NVIDIA (NASDAQ: NVDA) with its main competitors in the Semiconductors & Semiconductor Equipment sector. By looking at important...

Continue Reading
Invivyd Set to Showcase PEMGARDA™ Findings at Upcoming Event

Updated Category News Views 54

Invivyd Prepares for IDWeek 2024 Presentations Invivyd, Inc. (NASDAQ: IVVD) is an innovative biopharmaceutical company focusing on creating solutions for serious viral infections. As they gear up for their participation in IDWeek 2024, they will be unveiling exciting new data concerning their investigational monoclonal antibody, PEMGARDA™ (pemivibart). The conference is...

Continue Reading
The Rising Stars: Growth Potential of Key Investments

Updated Category News Views 95

Carnival made waves post-pandemic as it clawed its way back from meme stock purgatory. Traders watched the cruise line stumble but now see flickers of recovery amidst hefty debt burdens that peaked around $35 billion. Sure, they pulled in a whopping $1.7 billion net income in the last quarter, but those profit forecasts? All over the place—talk about a mixed bag. And...

Continue Reading
PharmAla Partners with Logistics Expert for Clinical Trials

Updated Category News Views 114

PharmAla Forms Strategic Alliance for Enhanced US Distribution PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a dedicated biotechnology company, is excited to share its latest strategic move aimed at improving service delivery in the United States. The company has engaged a trusted third-party logistics partner, specialized...

Continue Reading